The successful use of subcutaneous abatacept in refractory anti- human transcriptional intermediary factor 1-gamma dermatomyositis skin and oesphagopharyngeal disease

Rheumatology (Oxford). 2018 Oct 1;57(10):1866-1867. doi: 10.1093/rheumatology/key146.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Abatacept / therapeutic use*
  • Aged
  • Antirheumatic Agents / therapeutic use*
  • Dermatomyositis / drug therapy*
  • Dermatomyositis / genetics
  • Esophageal Diseases / drug therapy*
  • Esophageal Diseases / genetics
  • Female
  • Humans
  • Pharyngeal Diseases / drug therapy*
  • Pharyngeal Diseases / genetics
  • Transcription Factors / drug effects
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • TRIM33 protein, human
  • Transcription Factors
  • Abatacept